Important matters:
Kangzhe Pharmaceutical (00867): Singapore marketing license application for innovative drug rucotinib phosphate cream approved
Insili Intelligence (03696) plans to invest 302.5 million yuan to participate in the establishment of an investment fund
Benmao Technology (06731) signs a strategic cooperation agreement with a leading Korean intelligent robot company
Qingang Co., Ltd. (03369) plans to acquire Caofeidian high-quality bulk terminal assets and raise supporting capital from Hebei Port Group
Shoucheng Holdings (00697) subsidiary participated in investing in CICC Cainiao REIT
Dongpeng Beverage (09980) won industrial land in Zhengzhou for 98.05 million yuan to promote the construction of a production base in central China
Shiyao Group (01093): Phase II clinical trial of SYH2072 tablets for the treatment of uncontrolled hypertension and refractory hypertension was officially launched at the first research center in China
Chenlin Education (01593) enters into an acquisition framework agreement relating to possible acquisitions
Changjiang Life Technology (00775): Shunpu Pharmaceutical Technology will publish the latest pre-clinical data on the two cancer vaccines at SITC 2026
Cornerstone Pharmaceutical-B (02616) and Kimia Therapeutics reached a clinical development cooperation to jointly promote an innovative drug candidate targeting key repair pathways for solid tumors
Operating performance:
Yum China (09987) announced third quarter results, net profit of US$311 million increased 10% year over year